You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The FIDES-03 trial will assess derazantinib plus Lilly's anti-VEGFR2 drug for patients with advanced gastric cancer harboring FGFR genetic aberrations.
Based on the results of this Phase Ib/II trial, the drugmaker will explore the activity of TG4001 in a larger confirmatory study.
The Phase I/II GOBLET trial will assess pelareorep plus Tecentriq in pancreatic, colorectal, and anal cancer patients and explore biomarkers of response.
The company will discuss with the FDA the possibility of using these preliminary Phase I results as part of its registrational package for the agent.
The company's aim in the Beat AML subprotocol is to determine the safety, maximum tolerated dose, and response rate with dubermatinib and chemotherapy.
The study will assess the safety and anti-tumor activity of the IL-7 agent and the checkpoint inhibitor combination for patients with PD-L1-expressing NSCLC.
The Prostate Cancer Biomarker Enrichment and Treatment Selection Study will match patients to treatments based on liquid biopsy-based biomarker evaluation.
Using RNA and DNA sequencing to predict tumor site and detect gene alterations may allow patients with CUP to receive appropriate targeted treatment.
The company is studying lasofoxifene in combination with Eli Lilly's Verzenio in certain metastatic breast cancer patients with ESR1 mutations in their tumors.
Patients in the Phase II trial will receive infusions of autologous T cells that have been genetically engineered to remove the intracellular checkpoint CISH.